ライフサイエンスコーパス: cardiovascular

1 After TAVR, all-cause and cardiovascular 30-day mortality rates were 2.4% and 1.4%

2 Major cardiovascular adverse events-free survival was worse in

3 sting differing roles in the pathogenesis of cardiovascular and cerebral large-vessel disease compare

4 DME could be associated with an increase in cardiovascular and cerebrovascular adverse events.

5 To evaluate the cardiovascular and cerebrovascular safety of ranibizumab

6 -RLX) has emerged as a potential therapy for cardiovascular and fibrotic diseases, but its short in v

7 Cardiovascular and HF readmission rates were higher in t

8 emic atherosclerosis with associated adverse cardiovascular and limb events.

9 and renal dysfunction manifested later than cardiovascular and respiratory dysfunction.

10 idence evaluating the use of telemedicine in cardiovascular and stroke care and to provide consensus

11 Prevention and treatment of cardiovascular and thrombotic issues associated with nov

12 The CANVAS Program (Canagliflozin Cardiovascular Assessment Study) randomly assigned 10 14

13 er DRP1 inhibition alters the development of cardiovascular calcification.

14 eath in the year after hospital discharge as cardiovascular, cancer, infection-related, or other.

15 The rates of death from cardiovascular causes, fatal or nonfatal myocardial infa

16 nous thrombosis; 28 patients (2.4%) died for cardiovascular causes.

17 st 1 organ system of the renal, respiratory, cardiovascular, coagulation, and neurologic systems by d

18 Prevention of cardiovascular complications may be accomplished through

19 Type 2 diabetes (T2D) has many cardiovascular complications, including a thrombotic pro

20 ated with an increased risk of metabolic and cardiovascular complications.

21 to prevent and treat cancer therapy-induced cardiovascular complications.

22 n-based cohort of NHL survivors, preexisting cardiovascular conditions were associated with increased

23 ally Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions) Registry (53% male; mean age

24 ent, treatment of underlying and concomitant cardiovascular conditions, stroke prevention therapy, ra

25 ird most common cause of mortality among all cardiovascular conditions.

26 The rates of cardiovascular (CV) death, MI, and stroke as well as TIM

27 Purpose Our aim was to determine whether cardiovascular (CV) risk in patients with prostate cance

28 ing the mechanisms contributing to increased cardiovascular (CV) risk in PTSD will pave the way for d

29 onfidence interval, 2.01-4.36; P<0.001), and cardiovascular death (adjusted hazard ratio, 2.16; 95% c

30 Cardiovascular death at 30 days occurred in 221 of 9155

31 mposite of myocardial infarction, stroke, or cardiovascular death in patients with established athero

32 Society of Thoracic Surgeons score and cardiovascular death were recorded.

33 vents (eg, nonfatal myocardial infarction or cardiovascular death) and noncardiovascular death.

34 sk of CVD (myocardial infarction, stroke, or cardiovascular death); 2) a MedDiet intervention [supple

35 nd the risk of coronary heart disease death, cardiovascular death, and all-cause mortality by 28% (P=

36 Myocardial infarction, cardiovascular death, and repeat revascularization cumul

37 ibrillation, stroke, deep venous thrombosis, cardiovascular death, and total mortality.

38 The combined endpoint was cardiovascular death, MI, or stroke at 1 year.

39 mb ischemia, with similar composite rates of cardiovascular death, myocardial infarction, and stroke

40 acy end point was a composite of adjudicated cardiovascular death, myocardial infarction, or ischemic

41 3%-11%; P < .001) lower risk for subsequent cardiovascular death/first HF hospitalization in patient

42 yocardial infarctions, 156 HF events, and 38 cardiovascular deaths occurred.

43 g BRINP3, NOS2, and TBX5-are associated with cardiovascular development and function but are not in t

44 emodelling in the activation of EPDCs during cardiovascular development and repair.

45 more thorough understanding of sex-specific cardiovascular differences both at baseline and in disea

46 alcium (CAC) score, incident atherosclerotic cardiovascular disease (ASCVD) events, and atrial fibril

47 ith subclinical and clinical atherosclerotic cardiovascular disease (ASCVD).

48 those at increased risk for atherosclerotic cardiovascular disease (ASCVD).

49 The lack of research to characterize cardiovascular disease (CVD) and CVD risk factors in tra

50 ducing the risk of LVH explains the reported cardiovascular disease (CVD) benefits of intensive BP lo

51 ers [blood pressure within sodium intake and cardiovascular disease (CVD) context and low density lip

52 gression of diabetic vascular complications, cardiovascular disease (CVD), and cancer progression and

53 Medication nonadherence, a major problem in cardiovascular disease (CVD), contributes yearly to appr

54 diabetic rodents, inhibition of MGO prevents cardiovascular disease (CVD).

55 between the Mediterranean diet (MedDiet) and cardiovascular disease (CVD).We evaluated the associatio

56 1.5, 95% confidence interval: 1.4, 1.6) and cardiovascular disease (hazard ratio = 1.4, 95% confiden

57 prospective association of CAC with risk of cardiovascular disease and all-cause mortality among dia

58 eing is associated with an increased risk of cardiovascular disease and arrhythmias, with the most co

59 s a cluster of interrelated risk factors for cardiovascular disease and diabetes mellitus.

60 stools from individuals with atherosclerotic cardiovascular disease and healthy controls, identifying

61 They also had significantly higher rates of cardiovascular disease and hypotension.

62 tics, preventive strategies, and therapy for cardiovascular disease are reviewed.

63 The primary cause of death is cardiovascular disease at about 14 years.

64 8 countries with diabetes mellitus and known cardiovascular disease at entry into TECOS (Trial Evalua

65 ssel cerebral vascular disease or history of cardiovascular disease but lower odds of small-vessel ce

66 For other cardiovascular disease causes, the ratio ranged from 1.4

67 gher risk of being hospitalized and dying of cardiovascular disease compared with the general populat

68 Several cardiovascular disease conditions were clustered substan

69 These traits are risk factors for cardiovascular disease even below the diabetic threshold

70 Understanding the relative contributions of cardiovascular disease event types to the excess burden

71 inflammation (r=0.49; p<0.0001), and risk of cardiovascular disease events (standardised hazard ratio

72 ortions, and both increase the prevalence of cardiovascular disease events.

73 ls and 4 different presentations of incident cardiovascular disease in a contemporary population.

74 of cardiovascular dysfunction and programme cardiovascular disease in later life.

75 ith type 2 diabetes mellitus and established cardiovascular disease in the EMPA-REG OUTCOME trial (Em

76 Cardiovascular disease is a leading cause of death among

77 disease event types to the excess burden of cardiovascular disease is important for developing effec

78 variation underlying many heritable forms of cardiovascular disease is incompletely understood, even

79 there was no difference in nonfatal stroke, cardiovascular disease mortality, or all-cause mortality

80 Cardiovascular disease occurs at lower incidence in prem

81 of metabolites observed in association with cardiovascular disease outcomes.

82 The constant increase in cardiovascular disease rate coupled with significant dra

83 ecular markers and metabolomic signatures of cardiovascular disease risk (including branched-chain am

84 riglycerides, glucose, and insulin-increases cardiovascular disease risk by inducing oxidative stress

85 V and hepatitis C infected people among whom cardiovascular disease risk is elevated and liver diseas

86 The median 10-year atherosclerotic cardiovascular disease risk score of the cohort was 4.8%

87 plasma levels of each of the 156 Framingham Cardiovascular Disease Risk Score-associated proteins us

88 /10 y; r(2)=0.07; P=1.6x10(-7)) but not with cardiovascular disease severity at baseline.

89 Data suggest that the prediction of adult cardiovascular disease using a model comprised entirely

90 Those without prevalent cardiovascular disease were followed until their first C

91 ho were older, male, and had atherosclerotic cardiovascular disease were more likely to be approved,

92 evolocumab in patients with atherosclerotic cardiovascular disease when added to standard background

93 neous injection in patients at high risk for cardiovascular disease who had elevated LDL cholesterol

94 bA1c clinical categories for atherosclerotic cardiovascular disease, 0.701 for ADA fasting glucose co

95 ns and is largely attributable to death from cardiovascular disease, although cancer incidence and mo

96 kocyte telomere length (LTL) with all-cause, cardiovascular disease, and cancer mortality in 12,199 a

97 s with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease.

98 susceptibility to the development of cancer, cardiovascular disease, and diabetes has not been formal

99 ith cardiometabolic risk factors, history of cardiovascular disease, and radiologic evidence of cereb

100 ith several age-related disorders, including cardiovascular disease, cancer, decline in cognitive fun

101 ntribute to a variety of diseases, including cardiovascular disease, diabetes, and cancer.

102 lipid and signaling molecule associated with cardiovascular disease, is known to activate extracellul

103 ntent, which can have an important impact on cardiovascular disease, particularly in countries where

104 ships between sleep-disordered breathing and cardiovascular disease, presenting clinical and research

105 and prediabetes and those with high risk of cardiovascular disease, stroke, heart failure, and atria

106 fects nearly 1 of 3 women and contributes to cardiovascular disease, the leading cause of death in th

107 y be on the causal pathway between noise and cardiovascular disease, we examined the influence of lon

108 re among patients with diabetes mellitus and cardiovascular disease, which in turn could lead to redu

109 ers measured twice, 10 to 16 years apart, in cardiovascular disease-free women, considering either av

110 usion/(+)sepsis: HR 2.27, 95% CI 1.87-2.76], cardiovascular disease-specific survival [(+)transfusion

111 arker combinations pivotal for understanding cardiovascular disease.

112 nel blocker clinically used in patients with cardiovascular disease.

113 in patients with established atherosclerotic cardiovascular disease.

114 vated threefold to fourfold in patients with cardiovascular disease.

115 omes for patients with diabetes mellitus and cardiovascular disease.

116 mation and thereby preventing CKD-associated cardiovascular disease.

117 nd summarize the data linking epigenetics to cardiovascular disease.

118 duced perinatal nutrition programmes chronic cardiovascular disease.

119 incident type 2 diabetes and atherosclerotic cardiovascular disease.

120 ions, and to explore how these contribute to cardiovascular disease.

121 Parkinson's disease, multiple sclerosis and cardiovascular disease.

122 inuria, long-term risk factors for renal and cardiovascular disease.

123 men, diabetic women are at a higher risk of cardiovascular disease.

124 death/myocardial infarction in patients with cardiovascular disease.

125 ce, education, smoking status, diabetes, and cardiovascular disease.

126 ta2AR, whose ligands are used for asthma and cardiovascular disease.

127 rotective with respect to obesity-associated cardiovascular disease.

128 a cohort of 351 adults at risk for ischemic cardiovascular disease.

129 ssociates with obesity, type 2 diabetes, and cardiovascular disease.

130 hypertension, type 2 diabetes mellitus, and cardiovascular disease.

131 ctively consider and treat all patients with cardiovascular disease.

132 alt consumption can lead to hypertension and cardiovascular disease.

133 e endorsed aspirin for primary prevention of cardiovascular disease.

134 associated with the risk for and outcome of cardiovascular diseases (CVDs).

135 m to be specific for AAA compared with other cardiovascular diseases and related traits suggesting th

136 855 men, mean age: 47.8+/-3.5 years) free of cardiovascular diseases completed the Center of Epidemio

137 on have a 1.5 to 2 times higher incidence of cardiovascular diseases than their uninfected counterpar

138 el in blood over 500mg/dL is a biomarker for cardiovascular diseases, Alzheimer disease, pancreatitis

139 entive effects in atherosclerosis, and other cardiovascular diseases, must be translated into changes

140 to the understanding of the epidemiology of cardiovascular diseases, particularly stroke.

141 seases.The gut microbiota may play a role in cardiovascular diseases.

142 ion as alternative therapeutics for managing cardiovascular diseases.

143 it damage associated with the progression of cardiovascular diseases.

144 l aging and to various neurodegenerative and cardiovascular diseases.

145 ions mediated by 20-HETE in hypertension and cardiovascular diseases.

146 al significance of genetic variants in human cardiovascular diseases.

147 lmarks of endothelial dysfunction leading to cardiovascular disorders, but the underlying molecular m

148 receptor (A2AR) has long been implicated in cardiovascular disorders.

149 nic fetal hypoxia, trigger a fetal origin of cardiovascular dysfunction and programme cardiovascular

150 ergic support in the setting of inflammatory cardiovascular dysfunction.

151 These cardiovascular effects appear to be mediated by paracrin

152 -year cumulative incidence of death or major cardiovascular event has remained stable over time.

153 Major adverse cardiac and cardiovascular event rate at 30 days was low (4%) and oc

154 with ACS as in patients with non-ACS (major cardiovascular event, 8.0% versus 8.5%; P=0.83; revascul

155 9 (PCSK9) has been shown to be predictive of cardiovascular events (CVEs) in patients who are at high

156 y (32.2%) patients experienced intrahospital cardiovascular events (CVEs) including 281 (23.8%) with

157 Secondary outcomes included major adverse cardiovascular events (eg, nonfatal myocardial infarctio

158 incident type 1 and T2MI, and major adverse cardiovascular events (MACE, a composite of all-cause de

159 2 mg/L had a 25% reduction in major adverse cardiovascular events (multivariable adjusted hazard rat

160 ding attenuated nonsignificant risk of major cardiovascular events (OR, 0.985 [95% CI, 0.955-1.015]).

161 igh school, and college and above], previous cardiovascular events [yes or no], current smoker [yes o

162 of significant absolute increases of 1.2% in cardiovascular events and 0.4% in mortality with torcetr

163 ent SBP levels are associated with increased cardiovascular events and all-cause mortality.

164 ified by cardiac imaging, is associated with cardiovascular events and predisposes to the development

165 t disease by 27% (P=0.033) and major adverse cardiovascular events by 25% (P=0.037) during the initia

166 summary, compared to TASC, the proportion of cardiovascular events did not markedly decrease over the

167 ents with type 2 diabetes mellitus and prior cardiovascular events had higher rates of cardiovascular

168 in (hs-CRP) is independently associated with cardiovascular events in coronary artery disease (CAD) p

169 alongside the PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attac

170 onocyte-derived macrophages, predicts future cardiovascular events in the general population.

171 oronary and cardiovascular events, and total cardiovascular events including revascularization, as we

172 ipid and lipoprotein levels, and the risk of cardiovascular events involving 102837 participants from

173 onation, the risk of all-cause mortality and cardiovascular events is no higher than in healthy nondo

174 Whether it prevents cardiovascular events is uncertain.

175 he efficacy of NHE inhibitors on the risk of cardiovascular events may be enhanced when heart failure

176 in one who received placebo, and adjudicated cardiovascular events occurred in five who received tofa

177 profile (and numerically the lowest rate of cardiovascular events) over a 6-year period compared wit

178 e potassium concentrations with arrhythmias, cardiovascular events, and mortality.

179 Hard coronary and cardiovascular events, and total cardiovascular events i

180 ose did not reduce the risk of major adverse cardiovascular events, but did reduce the incidence of d

181 cts of canakinumab on rates of major adverse cardiovascular events, cardiovascular mortality, and all

182 e population and improved treatment of acute cardiovascular events, despite the efficacy of many ther

183 ), and 3.09 (0.96 to 8.78) for major adverse cardiovascular events, hospitalizations, and vascular ac

184 reduced regenerative capacity contribute to cardiovascular events, independent of conventional risk

185 o compare all-cause mortality, major adverse cardiovascular events, myocardial infarction (MI), or ta

186 rated fatty acid supplementation on clinical cardiovascular events, we update prior recommendations f

187 rs, dual antiplatelet therapy, and long-term cardiovascular events.

188 w-density lipoprotein cholesterol (LDL-C) on cardiovascular events.

189 urn could lead to reduced risk of downstream cardiovascular events.

190 in RA restores autonomic balance and reduces cardiovascular events.

191 t is likely to be recovered by prevention of cardiovascular events.

192 Secondary outcomes included major adverse cardiovascular events.

193 the study medications) a lower risk of major cardiovascular events; however, they also had lower isch

194 ood pressure was 138/84 with an unremarkable cardiovascular examination.

195 ementary and alternative treatments, such as cardiovascular exercise, acupuncture, omega-3 fatty acid

196 (pneumonitis, acute respiratory failure, and cardiovascular failure).

197 lopmental cardiac abnormalities and impaired cardiovascular function.

198 nual healthcare costs for those in favorable cardiovascular health (P<0.001) during Medicare eligibil

199 Preventive approaches should take baseline cardiovascular health into account.

200 A smartphone-based study of cardiovascular health is feasible, and improvements in p

201 DS AND We measured the Life's Simple 7 ideal cardiovascular health metrics in 4195 blacks in the JHS.

202 e strategies needed to promote equity in the cardiovascular health of African Americans require input

203 erosis Risk in Communities study (ARIC), the Cardiovascular Health Study (CHS), and the Reasons for G

204 3 free from CVD at baseline) from 3 studies: Cardiovascular Health Study (CHS), Atherosclerosis Risk

205 s and dietary patterns that are promoted for cardiovascular health to provide clinicians with accurat

206 ion can enhance overall health, particularly cardiovascular health, and improve survival in a gender-

207 Obesity has adverse effects on cardiovascular hemodynamics and cardiac structure and fu

208 an Apelin-13 by improving fluid homeostasis, cardiovascular hemodynamics recovery, and limiting kidne

209 Despite the importance of vasodilation in cardiovascular homeostasis and therapy, our structural u

210 ndocrine and autonomic responses to maintain cardiovascular homeostasis, a basic understanding of the

211 trongly associated with subsequent death and cardiovascular hospitalization in HFpEF and HFrEF.

212 osite global rank score (hierarchy of death, cardiovascular hospitalizations, and percent changes in

213 months, but only 4 of them were managed with cardiovascular-implantable electronic device removal and

214 The CAT-HF (Cardiovascular Improvements With MV-ASV Therapy in Heart

215 METHODS AND Data analyzed from the British Cardiovascular Intervention Society data set on all CTO-

216 We review building capacity for conduction cardiovascular intervention through strengthening health

217 published over a 10-year period in 5 leading cardiovascular journals were reviewed.

218 Cardiovascular magnetic resonance (CMR) can detect morph

219 resented with late gadolinium enhancement on cardiovascular magnetic resonance at the right ventricle

220 Cardiovascular magnetic resonance imaging has become an

221 This review will highlight some recent novel cardiovascular magnetic resonance imaging techniques, co

222 uterized tomographic coronary angiogram, and cardiovascular magnetic resonance imaging with late gado

223 )C]-acetate positron emission tomography and cardiovascular magnetic resonance imaging.

224 ergoing PVR were prospectively recruited for cardiovascular magnetic resonance performed before PVR (

225 xtracellular volume measures acquired during cardiovascular magnetic resonance promises to transform

226 the exposure to PM10 and the risks of fetal cardiovascular malformations.

227 Advances in cardiovascular medicine fueled by innovative clinical tr

228 CRISPR-Cas9 is to be used in the practice of cardiovascular medicine.

229 s already known about specific treatments in cardiovascular medicine.

230 llowing injury represents a major barrier in cardiovascular medicine.

231 njection (DHI) is one of the most prescribed cardiovascular medicines in China, its therapeutic indic

232 m-glucose cotransporter 2 inhibitor, reduced cardiovascular morbidity and mortality in patients with

233 Cardiovascular morbidity and mortality were hypothesized

234 actors associated with increased longer-term cardiovascular mortality and (2) incremental prognostic

235 lic BP <140 mm Hg) decreased MACE, including cardiovascular mortality and heart failure.

236 e echocardiography and a composite endpoint (cardiovascular mortality and hospitalization) were evalu

237 ficacy of statin-based therapies in reducing cardiovascular mortality in individuals with CKD seems t

238 r clot structure had increased all-cause and cardiovascular mortality risks (log rank P=0.004 and P=0

239 ates of major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality accord

240 y disease (PAD) is associated with increased cardiovascular mortality, and PAD risk factors overlap w

241 imary composite outcome (HF hospitalization, cardiovascular mortality, or aborted cardiac arrest), it

242 t risk factor for coronary heart disease and cardiovascular mortality.

243 d phenotyping for AMD; other eye conditions; cardiovascular, neurologic, gastrointestinal, and endocr

244 ide range of physiological processes, namely cardiovascular, neuronal, immune, respiratory, gastroint

245 Associations with cardiovascular, neuropsychiatric, and malignant diseases

246 All deaths were adjudicated as cardiovascular or noncardiovascular by a panel of WISE c

247 2 deaths were observed, of which 207 were of cardiovascular origin.

248 in the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Me

249 lar risk factors at target and major adverse cardiovascular outcomes among patients with T1DM.

250 or cardiovascular events had higher rates of cardiovascular outcomes compared with the primary preven

251 Evolocumab significantly reduced cardiovascular outcomes consistently in patients with an

252 Of the 5 cardiovascular outcomes examined in South Indian patient

253 Long-term trends in excess risk of death and cardiovascular outcomes have not been extensively studie

254 , a machine learning technique, to predict 6 cardiovascular outcomes in comparison to standard cardio

255 dependent and additive predictors of adverse cardiovascular outcomes in coronary artery disease patie

256 V) adaptive servo-ventilation (ASV) improved cardiovascular outcomes in hospitalized HF patients with

257 Ezetimibe improved cardiovascular outcomes when added to statin therapy in

258 isease at entry into TECOS (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).

259 or IL-17A in KC-Tie2 psoriasis mice improves cardiovascular outcomes, mice were treated systemically

260 mates of sodium and potassium excretion with cardiovascular outcomes.

261 kin to hypoxia feeds back on a wide range of cardiovascular parameters, including heart rate, arteria

262 ation of sympathetic outflow with effects on cardiovascular parameters.

263 nversely associated with T2DM development in cardiovascular patients.

264 This finding mandates adequate attention to cardiovascular preventive therapy after diagnosis of bre

265 Surgical and catheter-based cardiovascular procedures and adjunctive pharmacology ha

266 orm provides a basis for generating distinct cardiovascular progenitor populations that enable the de

267 ether leading experts in different fields of cardiovascular research.

268 d related traits suggesting that traditional cardiovascular risk factor management may only have limi

269 ociation exists between decreasing number of cardiovascular risk factors at target and major adverse

270 Survivors with cardiovascular risk factors had an increased risk of HF

271 Cardiovascular risk factors in midlife (specifically ele

272 hts the importance of lifelong monitoring of cardiovascular risk factors in women with a history of p

273 ng, gathering, fishing, and farming with few cardiovascular risk factors, but high infectious inflamm

274 ian persons and associated with conventional cardiovascular risk factors, stroke, and chronic kidney

275 onceptually as an accelerator of traditional cardiovascular risk factors.

276 for patients with serious mental illness and cardiovascular risk factors.

277 as compared with calcified plaque burden and cardiovascular risk factors.

278 HF compared with those with none (for 1 v 0 cardiovascular risk factors: HR, 1.63; 95% CI, 1.07 to 2

279 R, 1.63; 95% CI, 1.07 to 2.47; for >/= 2 v 0 cardiovascular risk factors: HR, 2.86; 95% CI, 1.56 to 5

280 dy, a community-based observational study of cardiovascular risk in black adults, we measured serum e

281 enous antioxidant and has been identified as cardiovascular risk in cohort studies, while the relatio

282 Increased cardiovascular risk in mothers having male offspring sug

283 To better define serum inflammatory and cardiovascular risk proteins, we used an OLINK high-thro

284 ovascular outcomes in comparison to standard cardiovascular risk scores.

285 1 to 399 to CAC5y>/=400, coronary and total cardiovascular risk were nearly 2-fold in comparison wit

286 C) is a well established metabolic marker of cardiovascular risk, however, its role in pulmonary arte

287 sity to type 2 diabetes mellitus with excess cardiovascular risk, represents a major public health bu

288 ar events (CVEs) in patients who are at high cardiovascular risk.

289 pportunities exist to improve the quality of cardiovascular secondary prevention care among patients

290 hed placebo, which was added to standardised cardiovascular secondary prevention therapy.

291 At 48 hours, the mean improvement in the cardiovascular Sequential Organ Failure Assessment (SOFA

292 by which sleep disturbances adversely affect cardiovascular structure and function.

293 he two White Papers from the fourth UC Davis Cardiovascular Symposium Systems Approach to Understandi

294 y approximately 2.71%, and the proportion of cardiovascular system malformation rose by 0.92% from 20

295 ed pharmacokinetic (PBPK) model of the human cardiovascular system was incorporated into 58 extended

296 fect on biological mechanisms related to the cardiovascular system, data on their clinical effects ar

297 ide complex at loading rates relevant to the cardiovascular system, varied from the lowest-affinity H

298 s been associated with chronic damage to the cardiovascular system.

299 her the use of composite end points in major cardiovascular trials has changed over time and examine

300 hemorrhagic stroke, disabling/fatal stroke, cardiovascular/unexplained death, all-cause death, and p